Biotech Business Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Biotech Business Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Rhabdomyosarcoma
New rhabdomyosarcoma study results from P.M. Mcnab et al described
June 29th, 2009
According to a study from the United States, "CD5 is a 67 KD glycoprotein receptor that is present on a variety of T lymphocytes and mantle zone lymphocytes and is used routinely for the diagnosis of lymphomas and thymic carcinomas. That CD5 may be useful in diagnosis of mesenchymal tumors was an incidental finding in our sarcoma practice." "This pilot study evaluated CD5 expression in benign and malignant muscle tumors in comparison to normal muscle. Search of our pathology database identified the following cases: leiomyomas (10), rhabdomyomas (3), leiomyosarcomas (33), and rhabdomyosarcomas (9). In some of these cases, non-neoplastic smooth muscle (10) and skeletal...
Source: Biotech Business Week (2009-06-29)
|
